Article 1

Breaking Issues in Canadian Drug Reimbursement

Bob Kamino
President
The Canadian Association for Healthcare Reimbursement

Article 2

CADTH’s Common Drug Review: Addressing Emerging Challenges
in a Changing Therapeutic Landscape

Matthew Brougham
Vice President, Products and Services
Canadian Agency for Drugs and Technologies in Health (CADTH)

Article 3

Government Trends in the Pharmaceutical Industry

Mark Ferdinand
Senior Director, Health and Economic Policy
Canada’s Research-Based Pharmaceutical Companies (Rx&D)

Article 4

Pricing & Reimbursement Dynamics in Europe

W. Neil Palmer
President & Principal Consultant
PDCI Market Access

Article 5

Alberta PLA Update: Spring 2012

Filip Palasz
Senior Manager
Pharmaceutical Funding and Guidance Branch
Alberta Health and Wellness

Article 6

Product Listing Agreements: Provincial Innovations and Developments

Alan West
Partner, Life Sciences
Gowlings LLP

Article 7

Pan Canadian Oncology Drug Review (p-CODR)

Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.

Article 8

Quebec Updates and New Developments – INESSS One Year Later

France Mignault
Director, Government Affairs
JANSSEN Inc.
Rx&D INESSS Committee Lead

Article 9

The Case for a Canadian Orphan Drugs Policy

Kelly Gorman
Program Director, Advocacy & Public Policy
Cystic Fibrosis Canada
Board Member
Canadian Organization for Rare Disorders (CORD)

Article 10

Orphan Drugs – Meeting Regulatory and Reimbursement Challenges

Alan West
Partner, Life Sciences
Gowlings LLP

Article 11

Regulatory Approach for Subsequent Entry Biologics (Biosimilars)
in Canada: Emerging Directions and Challenges

Kwasi A. Nyarko, PhD
Regulatory Science Advisor
Office of Policy and International Collaboration, Biologics
and Genetic Therapies Directorate, Health Canada

Article 12

Links Between Clinical Research, Market Access and
Drug Pricing

Dr. David Griller
Partner
SECOR Consulting

Article 13

NOC/C and Reimbursement Interface

Anne Tomalin
Strategic Regulatory and Safety
OptumInsight

Article 14

Private Drug Plans – Progress and Current Challenges

Suzanne Lepage
Private Health Plan Strategist
Suzanne Lepage Consulting

Article 15

Private Drug Plans – Progress and Current Challenges

Barbara Martinez
Principal
Mercer

Article 16

Patented Medicine Prices Review Board (PMPRB)

W. Neil Palmer
President & Principal Consultant
PDCI Market Access

Article 17

Risk Sharing Agreements – Impact, Opportunities, Concerns

Alain Boisvert, M.Sc (Pharm.)
Vice President, Market Access
Bristol-Myers Squibb Canada

Article 18

Risk Sharing Agreements – Impact, Opportunities, Concerns

Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.

Article 19

Everybody Wins! Using Innovation to Drive a Successful Path
from Clinical to Regulatory to Commercial to Payers to Patients

George Wyatt, B.Sc., MBA
Managing Director
Wyatt Health Management

Article 20

Potential Reform for Pharmaceuticals: The Case for
a National Universal Pharmacare

Marc-André Gagnon, PhD
Assistant Professor, School of Public Policy and Administration
Carleton University

Article 21

An Action Items for Life Sciences Stakeholders

Steve Sampson
Director, Health and Life Sciences
Global Public Affairs

Article 22

Action Items for Canada’s Life Sciences Stakeholders
and Regulators

Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.